文献速递类风湿关节炎

托珠单抗治疗类风湿关节炎的免疫原性低

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2016-12-22

结果显示,皮下和静脉制剂治疗后的抗药抗体发生率分别为1.5%和1.2%,且抗药抗体产生与药代动力学、安全性事件或疗效丧失均无相关性。

要点

  • 托珠单抗皮下和静脉制剂抗药抗体发生率分别为1.5%和1.2%。
  • 单药治疗与联用csDMARDs时抗药抗体发生率相当(0.7-2.0%)。
  • 抗药抗体产生与药代动力学、安全性事件或疗效丧失无相关性。

核心结论

  • 托珠单抗皮下和静脉制剂治疗类风湿关节炎的免疫原性风险低,无论单药还是联用csDMARDs。
  • 少数产生抗托珠单抗抗体的患者中,抗药抗体对药代动力学、疗效或安全性无明显影响。

研究设计与样本

  • 汇总5项托珠单抗皮下制剂和8项静脉制剂III期临床试验及1项静脉制剂临床药理学安全性研究的数据。

主要发现

  • 皮下制剂和静脉制剂治疗后抗药抗体发生率分别为1.5%和1.2%。
  • 单药治疗与联用csDMARDs的患者抗药抗体发生率相当(0.7-2.0%)。
  • 抗药抗体产生与药代动力学或安全性事件(包括过敏反应、超敏反应或注射部位反应)无相关性。
  • 产生抗药抗体的患者均未出现疗效丧失。

关键数值与推荐

  • 抗药抗体发生率:皮下制剂1.5%,静脉制剂1.2%。
  • 单药与联用csDMARDs时抗药抗体发生率范围为0.7-2.0%。

临床怎么用

  • 托珠单抗皮下或静脉制剂单药或联用csDMARDs治疗类风湿关节炎时,免疫原性风险低,无需常规因抗药抗体担忧而调整治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and safety observed in clinical trials. Anti-TCZ antibody development and its impact on safety and efficacy were evaluated in adult patients with RA treated with intravenous TCZ (TCZ-IV) or TCZ-SC as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: Data from 5 TCZ-SC and 8 TCZ-IV phase III clinical trials and 1 TCZ-IV clinical pharmacology safety study (>50 000 samples) were pooled to assess the immunogenicity profile of TCZ-SC and TCZ-IV (8974 total patients). The analysis included antidrug antibody (ADA) measurement following TCZ-SC or TCZ-IV treatment as monotherapy or in combination with csDMARDs, after dosing interruptions or in TCZ-washout samples, and the correlation of ADAs with clinical response, adverse events or pharmacokinetics (PK). RESULTS: The proportion of patients who developed ADAs following TCZ-SC or TCZ-IV treatment was 1.5% and 1.2%, respectively. ADA development was also comparable between patients who received TCZ monotherapy and those who received concomitant csDMARDs (0.7-2.0%). ADA development did not correlate with PK or safety events, including anaphylaxis, hypersensitivity or injection-site reactions, and no patients who developed ADAs had loss of efficacy. CONCLUSIONS: The immunogenicity risk of TCZ-SC and TCZ-IV treatment was low, either as monotherapy or in combination with csDMARDs. Anti-TCZ antibodies developed among the small proportion of patients had no evident impact on PK, efficacy or safety.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Burmester GR, Choy E, Kivitz A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016. PMID: 28007755. doi:10.1136/annrheumdis-2016-210297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。